Visfatin/NAMPT: A multifaceted molecule with diverse roles in physiology and pathophysiology

Annual Review of Nutrition

Volumn 32, Issue , 2012, Pages 229-243

  Dahl, Tuva B ^a,b   Holm, Sverre ^a,b   Aukrust, Pal ^a,b   Halvorsen, Bente ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atherosclerosis; Cytokine; Intracellular enzyme; Metabolic disorders; NAD signaling

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN;

ADAPTATION; ADENOSINE DIPHOSPHATE RIBOSYLATION; ADIPOCYTE; ADIPOSE TISSUE; AGING; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BRAIN; DEGENERATIVE DISEASE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY DISEASE; LIPID STORAGE; LIVER; MACROPHAGE; METABOLIC DISORDER; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPTICEMIA; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; EXTRACELLULAR MATRIX; HUMANS; LIPID METABOLISM; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIGNAL TRANSDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84864269536     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071811-150746     Document Type: Review

References (98)

1. Adya R, Tan BK, Chen J, Randeva HS. 2008. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31:758-60
2. Adya R, Tan BK, Chen J, Randeva HS. 2009. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 205:113-19
3. Adya R, Tan BK, Punn A, Chen J, Randeva HS. 2008. Visfatin induces human endothelial VEGF and MMP-2/9 production viaMAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78:356-65 (Pubitemid 351556097)
4. Ba X, Garg NJ. 2011. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am. J. Pathol. 178:946-55
5. Belenky P, Bogan KL, Brenner C. 2007. NAD+ metabolism in health and disease. Trends Biochem. Sci. 32:12-19
6. Bennett MR. 1999. Apoptosis of vascular smoothmuscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. 41:361-68 (Pubitemid 29087332)
7. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, et al. 2005. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911-16 (Pubitemid 41401086)
8. Bi J, Li H, Ye SQ, Ding S. 2012. Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models. J. Neurochem. 120:334-46
9. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, et al. 2007. Pre-B cell colony-enhancing factor/ visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrixdegrading activities. Arthritis Rheum. 56:2829-39 (Pubitemid 47502729)
10. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011-15 (Pubitemid 38393275)
11. Chang L, Yang R, Wang M, Liu J, Wang Y, et al. 2012. Angiotensin II type-1 receptor-JAK/STAT pathway mediates the induction of visfatin in angiotensin II-induced cardiomyocyte hypertrophy. Am. J. Med. Sci. 343:220-26
12. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. 2011. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab. Res. Rev. 27:515-27
13. Chen H, XiaT, Zhou L, ChenX, Gan L, et al. 2007. Gene organization, alternate splicing and expression pattern of porcine visfatin gene. Domest. Anim. Endocrinol. 32:235-45
14. Chen MP, Chung FM, ChangDM, Tsai JC, HuangHF, et al. 2006. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91:295-99 (Pubitemid 43069152)
15. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. 1999. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342(Pt. 2):249-68 (Pubitemid 29425344)
16. Dahl T, Ranheim T, Holm S, Berge R, Aukrust P, Halvorsen B. 2011. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur. J. Clin. Invest. 41:1098-104
17. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, et al. 2010. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 95:3039-47
18. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, et al. 2007. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972-80 (Pubitemid 46328290)
19. Fantuzzi G. 2005. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 115:911-19
20. Fernandez-Real JM, Moreno JM, Chico B, Lopez-Bermejo A, Ricart W. 2007. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 30:616-21 (Pubitemid 46354343)
21. Forman D, Bulwer BE. 2006. Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle. Curr. Treat. Options Cardiovasc. Med. 8:47-57 (Pubitemid 43137245)
22. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-30 (Pubitemid 40139988)
23. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. 2007. Erratum (retracted article). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 318:565 (Pubitemid 350014814)
24. Garten A, Petzold S, Barnikol-Oettler A, Korner A, ThaslerWE, et al. 2010. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem. Biophys. Res. Commun. 391:376-81
25. Geng YJ, Libby P. 2002. Progression of atheroma: a struggle between death and procreation. Arterioscler. Thromb. Vasc. Biol. 22:1370-80
26. Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, et al. 2008. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum. 58:1399-409 (Pubitemid 351705929)
27. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, et al. 2008. Atherosclerotic plaque stability-what determines the fate of a plaque? Prog. Cardiovasc. Dis. 51:183-94
28. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:1685-9529. Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M.
29. Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M. 2011. Nicotinamide phosphoribosyltransferase/ visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE 6:e22781
30. Hasmann M, Schemainda I. 2003. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63:7436-42 (Pubitemid 37413486)
31. Hausenloy DJ. 2009. Drug discovery possibilities from visfatin cardioprotection? Curr. Opin. Pharmacol. 9:202-7
32. Imai S, Armstrong CM, Kaeberlein M, Guarente L. 2000. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403:795-800 (Pubitemid 30111843)
33. Jia SH, Li Y, Parodo J, Kapus A, Fan L, et al. 2004. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 113:1318-27 (Pubitemid 39069931)
34. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, et al. 2010. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 118:75-80
35. Kendal-Wright CE, Hubbard D, Bryant-Greenwood GD. 2008. Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis. Placenta 29:255-65
36. Kim MY, Zhang T, Kraus WL. 2005. Poly(ADP-ribosyl)ation by PARP-1: "PAR-laying" NAD+ into a nuclear signal. Genes Dev. 19:1951-67
37. Kockx MM, Herman AG. 2000. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res. 45:736-46 (Pubitemid 30047141)
38. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, et al. 2005. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur. J. Dermatol. 15:251-57 (Pubitemid 41020851)
39. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. 2007. Molecular characteristics of serum visfatin and differential detection by immunoassays. J. Clin. Endocrinol. Metab. 92:4783-91 (Pubitemid 350223461)
40. Krzysik-Walker SM, Ocon-Grove OM, Maddineni SR, Hendricks GL III, Ramachandran R. 2008. Is visfatin an adipokine ormyokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 149:1543-50 (Pubitemid 351468312)
41. Kutuk O, Basaga H. 2003. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol. Med. 9:549-57 (Pubitemid 38017194)
42. Landry J, Slama JT, Sternglanz R. 2000. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem. Biophys. Res. Commun. 278:685-90
43. Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, et al. 2010. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.Horm. Metab. Res. 42:268-73
44. Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, et al. 2009. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int. J. Obes. (Lond.) 33:465-72
45. Leonard WJ, Lin JX. 2000. Cytokine receptor signaling pathways. J. Allergy Clin. Immunol. 105:877-88 (Pubitemid 30324393)
46. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. 2007. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28:91-106 (Pubitemid 47531974)
47. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, et al. 2008. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 283:34833-43
48. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-74 (Pubitemid 36019640)
49. Littlewood TD, BennettMR.2003. Apoptotic cell death in atherosclerosis. Curr. Opin. Lipidol. 14:469-75 (Pubitemid 37297301)
50. Liu SW, Qiao SB, Yuan JS, Liu DQ. 2009. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin. Endocrinol. (Oxf.) 71:202-7
51. Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, et al. 2009. Elevated visfatin/pre-B-cell colonyenhancing factor plasma concentration in ischemic stroke. J. Stroke Cerebrovasc. Dis. 18:354-59
52. Magni G, Amici A, Emanuelli M, Raffaelli N, Ruggieri S. 1999. Enzymology of NAD+ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 73:135-82
53. Martin PR, Shea RJ, Mulks MH. 2001. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J. Bacteriol. 183:1168-74 (Pubitemid 32107712)
54. Michan S, Sinclair D. 2007. Sirtuins in mammals: insights into their biological function. Biochem. J. 404:1-13 (Pubitemid 46788079)
55. Moschen AR, Gerner RR, Tilg H. 2010. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr. Pharm. Des. 16:1913-20
56. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. 2007. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178:1748-58 (Pubitemid 46154646)
57. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al. 2004. Mammalian SIRT1 represses forkhead transcription factors. Cell 116:551-63 (Pubitemid 38264432)
58. Murray CJ, Lopez AD. 1997. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-42 (Pubitemid 27212192)
59. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. 2009. Circadian control of the NAD +salvage pathway by CLOCK-SIRT1. Science 324:654-57
60. Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ. 2010. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt-and MAPK-independent, NF?B-dependent manner. Pflugers Arch. 459:619-30
61. Otero M, Lago R, Gomez R, Lago F, Dieguez C, et al. 2006. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin, and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65:1198-1201 (Pubitemid 44277396)
62. Patel ST, Mistry T, Brown JE, Digby JE, AdyaR, et al. 2010. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 31:51-57
63. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-76 (Pubitemid 38833129)
64. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, et al. 2010. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals amitochondrial insensitiveNADpool. J. Biol. Chem. 285:34106-14
65. Preiss J, Handler P. 1957. Enzymatic synthesis of nicotinamide mononucleotide. J. Biol. Chem. 225:759-70
66. Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, et al. 2008. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a crosssectional study. Clin. Endocrinol. (Oxf.) 69:885-93
67. Revollo JR, Grimm AA, Imai S. 2004. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279:50754-63 (Pubitemid 40017813)
68. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, et al. 2007. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6:363-75 (Pubitemid 350011996)
69. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113-18 (Pubitemid 40349395)
70. Romacho T, Azcutia V, Vazquez-Bella M, Matesanz N, Cercas E, et al. 2009. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52:2455-63
71. Rongvaux A, Galli M, Denanglaire S, Van GF, Dreze PL, et al. 2008. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 181:4685-95
72. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, et al. 2002. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32:3225-34 (Pubitemid 35414880)
73. Rutanen J, Yaluri N, Modi S, Pihlajamaki J, VanttinenM, et al. 2010. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes 59:829-35
74. Samal B, Sun Y, StearnsG, Xie C, Suggs S, McNiece I. 1994. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14:1431-3776. Schrijvers DM, De Meyer GR, Herman AG, Martinet W.
75. Schrijvers DM, De Meyer GR, Herman AG, Martinet W. 2007. Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Cardiovasc. Res. 73:470-80 (Pubitemid 46073944)
76. Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, et al. 2009. NAMPT is essential for the G-CSFinduced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat. Med. 15:151-58
77. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, et al. 2000. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. USA 97:6658-63 (Pubitemid 30412770)
78. Sommer G, Kralisch S, Kloting N, Kamprad M, Schrock K, et al. 2009. Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obesity (Silver Spring) 18:1486-92
79. Tabas I. 2005. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25:2255-64 (Pubitemid 41552640)
80. Tabas I. 2007. Apoptosis and efferocytosis inmousemodels of atherosclerosis. Curr. Drug Targets 8:1288-96
81. Tabas I. 2010. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10:36-46
82. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, et al. 2007. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem. Biophys. Res. Commun. 359:194-201 (Pubitemid 46880493)
83. van der Veer, Nong Z, ONeil C, Urquhart B, Freeman D, Pickering JG. 2005. Pre-B-cell colonyenhancing factor regulatesNAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ. Res. 97:25-34 (Pubitemid 40982319)
84. Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, et al. 2009. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 15:206-10
85. Wang LS, Yan JJ, Tang NP, Zhu J, Wang YS, et al. 2010. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol. Biol. Rep. 38:819-25
86. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. 2009. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc. Res. 81:370-80
87. Wang T, ZhangX, Bheda P, Revollo JR, Imai S, Wolberger C. 2006. Structure ofNampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 13:661-62 (Pubitemid 44036478)
88. World Health Org. 2009. Cardiovascular Diseases (CVDs). Fact Sheet No. 317. Geneva: WHO. http://www.who.int/mediacentre/factsheets/fs317/en/index.html
89. Xie H, Tang SY, Luo XH, Huang J, Cui RR, et al. 2007. Insulin-like effects of visfatin on human osteoblasts. Calcif. Tissue Int. 80:201-10 (Pubitemid 46411878)
90. Yang CC, Deng SJ, Hsu CC, Liu BH, Lin EC, et al. 2010. Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J. Anim. Sci. 88:3233-41
91. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, et al. 2005. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am. J. Respir. Crit. Care Med. 171:361-70 (Pubitemid 40223404)
92. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. 2004. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:2369-80 (Pubitemid 38954844)
93. Young JL, Libby P, Schonbeck U. 2002. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88:554-67 (Pubitemid 35173995)
94. Zhai RG, Rizzi M, Garavaglia S. 2009. Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, new insights into an ancient enzyme. Cell Mol. Life Sci. 66:2805-18
95. Zhang T, Berrocal JG, Frizzell KM, Gamble MJ, DuMond ME, et al. 2009. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J. Biol. Chem. 284:20408-17
96. ZhangX, MosserDM. 2008. Macrophage activation by endogenous danger signals. J. Pathol. 214:161-78
97. ZhongM, Tan HW, GongHP, Wang SF, Zhang Y, ZhangW. 2008. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin. Endocrinol. (Oxf.) 69:878-84
98. ZongWX, DitsworthD, Bauer DE, WangZQ, Thompson CB. 2004. AlkylatingDNAdamage stimulates a regulated form of necrotic cell death. Genes Dev. 18:1272-82 (Pubitemid 38720595)